Mirae Asset Global Investments Co. Ltd. Purchases 1,418 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) by 8.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,893 shares of the company’s stock after purchasing an additional 1,418 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Cassava Sciences were worth $403,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SAVA. Montag A & Associates Inc. boosted its holdings in shares of Cassava Sciences by 50.0% during the 3rd quarter. Montag A & Associates Inc. now owns 1,500 shares of the company’s stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Impact Partnership Wealth LLC bought a new position in shares of Cassava Sciences during the 3rd quarter valued at about $25,000. Headlands Technologies LLC boosted its holdings in shares of Cassava Sciences by 24,044.4% during the 3rd quarter. Headlands Technologies LLC now owns 2,173 shares of the company’s stock valued at $36,000 after purchasing an additional 2,164 shares during the last quarter. NBC Securities Inc. bought a new position in shares of Cassava Sciences during the 3rd quarter valued at about $66,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Cassava Sciences by 74.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,633 shares of the company’s stock valued at $77,000 after acquiring an additional 1,979 shares during the last quarter. Institutional investors own 38.05% of the company’s stock.

Cassava Sciences Trading Up 2.8 %

Shares of NASDAQ:SAVA opened at $22.34 on Friday. Cassava Sciences, Inc. has a 12 month low of $12.32 and a 12 month high of $32.10. The company has a 50-day moving average price of $21.41 and a 200 day moving average price of $20.02. The company has a market cap of $966.21 million, a price-to-earnings ratio of -9.63 and a beta of -0.45.

Cassava Sciences (NASDAQ:SAVA) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). As a group, equities analysts forecast that Cassava Sciences, Inc. will post -2.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $124.00 price target on shares of Cassava Sciences in a report on Tuesday, March 5th.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.